Why Arena Pharmaceuticals Shares Are Rocketing 31.6% Higher Today

After the company unveiled phase 2 data results for its clinical-stage ulcerative colitis drug, etrasimod, shares in Arena Pharmaceuticals (NASDAQ: ARNA) are shooting 31.6% higher as of 1 p.m. EDT today.The ulcerative colitis market is worth billions of dollars in sales annually. Arena Pharmaceuticals hopes etrasimod can vie for a share of that market someday, if late-stage data confirm results from its midstage study.IMAGE SOURCE: GETTY IMAGES.Continue reading

BING NEWS:
  • Fund offering 'venture capital' exposure sends investors on meme-like ride
    A new fund that allows shareholders access to privately owned technology companies has sent investors on a wild ride in recent weeks while eliciting criticism from the likes of Morningstar and ...
    04/23/2024 - 2:29 am | View Link
  • Arena Pharmaceuticals
    Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers ...
    04/18/2024 - 1:00 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News